DEVELOPMENT OF IMMUNOTHERAPIES FOR CHRONIC MYELOID LEUKEMIA

慢性粒细胞白血病免疫疗法的开发

• 批准号: 6314040
• 负责人: JAMES DOUGLAS GRIFFIN
• 金额: $ 22.61万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-05-10 至 2002-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6314040
• 关键词: antigen presenting cell; chronic myelogenous leukemia; disease /disorder model; genetic enhancer element; genetic promoter element; genetically modified animals; immune tolerance /unresponsiveness; laboratory mouse; model design /development; molecular cloning; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; tissue /cell culture; tumor antigens

At present, curative therapy for CML is limited primarily to the small fraction of patients with stable phase disease who are eligible for an HLA- matched bone marrow transplant. There has recently been renewed interest in developing immunotherapies for cancer because of a number of discoveries in basic immunology. These discoveries include major advances in the understanding of antigen presentation, T cell regulation, and the mechanisms of tolerance or anergy. In theory, many cancers have potential tumor antigens in the form of mutations in dominant oncogenes, viral oncogenes, or other neoantigens. CML is an example, where the p210 BCR/ABL oncogene itself is a possible tumor antigen, as are mutations in other proto-oncogenes such as p53 and p21 ras which are commonly observed in advanced forms of the disease. It is evident that most or all patients with CML generate either no immune response to athe tumor or an ineffective immune response. The immune response to leukemia cells may be impaired because leukemic antigens are typically presented to T cells in such a manner as to force the development of tolerance rather than active immunity. Tolerance is believed to be caused by the presentation of antigen to T cells in the absence of a costimulatory signal through CD28. The goals of this project will be to develop animal models to explore the immune response to a leukemia antigen (p210BCR/ABL), to investigate ways of manipulating the immune response in vivo as a correlate to in vitro studies with human cells conducted in other projects, to find novel ways to induce an effective immune response in leukemic animal which could lead to clinical trials, and to generate new animal models of CML which more accurately reflect human disease. This models produced by this project will also be used by investigators in other projects to test new concepts about tolerance or techniques for altering immune responses to tumors. Over the long term, this project should contribute tot he development of novel therapies for human leukemias and lymphomas.

目前，慢性粒细胞白血病的治疗主要局限于小患者。 有资格接受人类白细胞抗原的稳定期疾病患者的比例- 匹配的骨髓移植。最近，人们对此重新产生了兴趣 在开发癌症免疫疗法方面，因为一些发现 在基础免疫学方面。这些发现包括在 了解抗原提呈、T细胞调节和 耐受或无能的机制。从理论上讲，许多癌症都有潜在的可能性 以显性癌基因突变形式的肿瘤抗原，病毒 癌基因或其他新抗原。CML就是一个例子，其中p210 BCR/ABL 癌基因本身可能是一种肿瘤抗原，其他基因的突变也是如此 原癌基因，如p53和p21ras，通常在 这种疾病的晚期形式。很明显，大多数或所有患者 CML要么对肿瘤没有免疫反应，要么无效 免疫反应。对白血病细胞的免疫反应可能受损。 因为白血病抗原通常被提呈给这样的T细胞 强迫发展宽容而不是积极的态度 豁免权。耐受性被认为是由于 在没有共刺激信号的情况下通过CD28将抗原转移到T细胞。 该项目的目标将是开发动物模型来探索 白血病抗原(p210BCR/ABL)的免疫应答 在体内操纵免疫反应与体外研究的相关性 与人类细胞在其他项目中进行合作，寻找新的方法来诱导 白血病动物的有效免疫反应可能导致 临床试验，并产生新的慢性粒细胞白血病动物模型 准确反映人类疾病。这个项目生产的这个模型 也将被其他项目的研究人员用来测试新概念 关于耐受性或改变肿瘤免疫反应的技术。 从长远来看，这个项目应该有助于 人类白血病和淋巴瘤的新疗法。